Welcome to our dedicated page for Neogenomics SEC filings (Ticker: NEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to NeoGenomics, Inc. (NASDAQ: NEO) SEC filings, offering a regulatory view of the company’s activities as a public cancer diagnostics business. NeoGenomics is a Nevada corporation with common stock listed on The Nasdaq Stock Market LLC under the symbol NEO, as disclosed in its Form 8-K filings.
Investors can review current reports on Form 8-K, which NeoGenomics uses to furnish quarterly financial results, preliminary revenue updates, and information about board and executive changes. Recent 8-K filings have reported results for fiscal quarters, described financial metrics such as revenue and operating expenses, and documented director appointments and resignations.
Through this page, users can also monitor quarterly and annual reports (Forms 10-Q and 10-K when available) that typically include detailed discussions of the company’s oncology diagnostics operations, risk factors, and financial statements. These filings complement the company’s news releases describing clinical test volumes, next-generation sequencing contributions, and research and development spending.
For those tracking governance and corporate actions, the SEC filings detail matters such as board composition and compensation arrangements for directors, as reflected in 8-K disclosures about board changes. Filings related to financial results often reference non-GAAP measures like Adjusted EBITDA and Adjusted Gross Profit Margin, with reconciliations and definitions included in the attached press releases.
Stock Titan enhances these documents with AI-powered summaries that explain key points from lengthy filings, highlight notable changes from prior periods, and make it easier to locate items related to revenue trends, operating performance, and governance updates. Real-time updates from EDGAR help ensure that new NeoGenomics filings, including any future Forms 10-K, 10-Q, or Form 4 insider transaction reports, are quickly reflected and summarized for NEO investors and researchers.
NeoGenomics reported select preliminary, unaudited revenue results for the fourth quarter and full year ended December 31, 2025, while emphasizing that these figures are based on management estimates and may change after the year-end audit.
The company also outlined a planned finance leadership transition. Chief Financial Officer Jeffrey S. Sherman notified the board of his intention to retire and will move to Executive Vice President, Finance on March 2, 2026, serve in that role until April 14, 2026, and then act as a special advisor through April 2028. Abhishek Jain has been appointed Executive Vice President, Finance and is expected to become Chief Financial Officer on March 2, 2026. His compensation includes a $520,000 annual base salary, a target annual bonus equal to 60% of salary, and an initial equity award valued at $2,750,000 split evenly between three-year vesting restricted stock units and premium-priced stock options.
NeoGenomics, Inc. reported Q3 2025 results with net revenue of $187.8 million, up from $167.8 million a year ago, as testing volumes and payer mix lifted sales. Gross profit was $80.4 million. The company posted a net loss of $27.1 million (basic and diluted loss per share of $0.21), reflecting higher operating expenses and impairment charges.
Operating loss was $27.0 million, including a $7.1 million impairment tied to a business classified as held for sale. Year to date, net revenue reached $537.2 million and net loss was $98.1 million. Cash and cash equivalents were $164.1 million as of September 30, 2025, after repaying $201.3 million of 2025 convertible notes and $1.3 million of interest in May. Operating cash flow was $3.9 million for the first nine months.
The company closed the Pathline acquisition for $8.5 million; Pathline contributed $4.6 million of revenue in Q3 and recorded a net loss of $2.2 million. Assets held for sale related to Trapelo totaled $2.1 million, and total impairment for the disposal group was $15.3 million year to date. As of October 24, 2025, shares outstanding were 129,387,801.
NeoGenomics, Inc. (NEO) announced that it furnished a press release reporting results for its third fiscal quarter of 2025. The press release, dated October 28, 2025, is included as Exhibit 99.1.
The company states this information is furnished and is not deemed “filed” under Section 18 of the Exchange Act, and it is incorporated by reference only if specifically referenced in other filings.
NeoGenomics (NEO) executive Alicia C. Olivo (EVP, GC & Business Development) reported an open-market sale of common stock. On 10/16/2025, she sold 4,918 shares at $10.00 per share under a Rule 10b5-1 trading plan. Following this transaction, she beneficially owns 43,022 common shares directly.
Her equity awards include multiple grants shown in the filing, such as stock options with exercise prices ranging from $9.45 to $48.99, and time- and performance-based stock units, including 107,450 options with a $13.05 exercise price and 63,238 restricted stock units. The filing notes standard vesting schedules and that once vested, shares of common stock are not subject to expiration.
Alicia C. Olivo, EVP, General Counsel & Business Development of NeoGenomics, reported a Form 4 reflecting a tax-related surrender and extensive outstanding equity awards. On 09/01/2025 she surrendered 1,666 shares to NeoGenomics to satisfy tax withholding upon the vesting of restricted stock, leaving 47,940 shares of common stock beneficially owned. The filing lists multiple stock options, restricted stock units (RSUs) and performance stock units (PSUs) across grants from 2019 through 2025, including large awards on 02/21/2025 of 107,450 options and 63,238 RSUs. Several PSUs have maximum payout caps (e.g., 19,508 target with 29,262 max; 25,330 target with 37,996 max) tied to share-price and revenue goals. Many options vest ratably over 3–4 years and, once vested, shares do not expire.
Neogenomics, Inc. Schedule 13G discloses that First Light Asset Management, LLC beneficially holds 9,544,749 shares of Neogenomics common stock (about 7.39% of the class). Mathew P. Arens is reported as beneficial owner of 9,784,749 shares (about 7.57%), which reflects his control of the manager plus 100,000 shares held directly and additional shares held jointly. The filing is submitted under Rule 13d-1(b), indicating these holdings are reported as passive and not intended to change or influence control of the issuer. The filing includes a joint filing agreement and identifies the reporting persons' business address.
Three related reporting persons — Greenhouse Funds LLLP, Greenhouse GP LLC and Joseph Milano — each report beneficial ownership of 7,431,147 shares of NeoGenomics common stock, representing 5.8% of the class. The filing shows no sole voting or dispositive power and reports shared voting power of 6,658,116 and shared dispositive power of 7,431,147, indicating joint control over voting and disposition rather than individual control.
The statement explains these securities are directly owned by advisory clients of Greenhouse Funds LLLP, that the holdings were acquired and are held in the ordinary course of business and were not acquired to influence control of the issuer, and includes a disclaimer limiting claimed beneficial ownership to pecuniary interest.
NeoGenomics disclosed that director Elizabeth Floegel resigned from the Company’s Board, effective immediately. The filing expressly states her resignation did not result from any disagreement with the Company on its operations, policies or practices. The notice is a straightforward governance update recorded under Item 5.02 and does not include any additional information about reasons beyond the statement or any immediate replacement for the Board seat.
This disclosure informs investors of a change in board composition while explicitly denying any dispute with management; the filing contains no financial data, operational changes or other material transactions.
Key takeaways from CEO Anthony P. Zook’s Form 4 filing (NEO, filed 6 Aug 2025):
- On 06 Aug 2025 Zook executed an open-market purchase (code P) of 17,900 common shares at $5.584, raising his direct stake to 38,066 shares; he also beneficially owns 18,900 shares via a trust.
- No shares were sold or otherwise disposed.
- Derivative holdings disclosed: 8,353 options @ $14.82 (exercisable 10 Aug 2024–10 Aug 2033), 8,672 options @ $13.71 (1 Jun 2025–1 Jun 2034) and a premium-priced grant of 729,927 options @ $10.44. In addition, 421,496 restricted stock units were granted on 1 Apr 2025. All awards vest ratably over three years.
The net effect is an incremental cash purchase signalling management confidence at a price well below option strikes, while the large option/RSU package further aligns incentives but introduces future dilution risk.